Abstract:PL07-02 Purpose: Genetic polymorphisms contribute to interindividual variation in drug response. Understanding how specific genetic variants modify drug action pathways may provide informative blueprints for individualized chemotherapy. However, a single polymorphism is likely to exhibit a modest effect. Therefore, we applied a pathway-based approach to evaluate the cumulative effect of multiple polymorphisms on clinical outcome of patients with non-small cell lung cancer (NSCLC). Methods: We genotyped 25 functional polymorphisms in 16 key genes involved in cisplatin metabolism and drug action and evaluated their associations with overall survival in 229 NSCLC patients receiving first-line cisplatin-based chemotherapy. The Cox proportional hazard model was used to assess the effect of individual polymorphisms on overall survival, Kaplan-Meier curves and log-rank tests were used to assess the differences in survival by individual polymorphisms. We then performed a pathway-based analysis by counting the number of putative unfavorable genotypes. Survival tree analyses using recursive-partitioning were also performed to investigate higher order gene-gene interactions and identify subgroups of individuals at higher risk of death. We finally constructed receiver operating characteristic (ROC) curves and calculated the area under the curve (AUC) to evaluate the specificity and sensitivity of predicting death and survival by clinical variables only, and by the combination of clinical, epidemiological, and genetic variables. Results: Several biologically plausible main effects were identified in individual analysis. Among nucleotide excision repair (NER) pathway genes, patients carrying the rare homozygous RAD23 Ala249Val genotype exhibited significantly poorer survival (HR= 2.08, 95% CI, 1.04 to 4.16). An ERCC1 3’ UTR SNP (rs3212986) variant-containing genotypes (GT+TT) exhibited significantly improved overall survival (HR=0.68, 95%CI, 0.48-0.95). Kaplan-Meier estimates demonstrated that the median survival time (MST) for individuals with the ERCC1 GT+TT genotypes was 15.8 months compared with MST for the wild-type GG genotype of 12.1 months. We then assumed an additive model and summed the unfavorable genotypes in the NER pathway. These unfavorable genotypes were XPA 5’ UTR A23G (AG/GG), XPC intron9 poly-AT (-), XPD Lys751Gln (AA/AC), CCNH Val270Ala (TT/TC), RAD23 (TT), and ERCC1 (GG). There was a trend of reduced risk of death with decreasing number of unfavorable genotypes. Compared with patients >4 unfavorable genotypes, the HRs for patients with 3-4, and 4, 3 to 4, and 1.2). Kaplan-Meier estimates were plotted for three representative nodes selected from each risk group. Terminal node 1 was in the low-risk group with a MST of 22.6 months, terminal node 3 was in the medium-risk group with a MST of 17.7 months, and terminal node 4 was in the high-risk group with a MST of 9.27 months (log rank P 4) and used Kaplan-Meier survival curves to plot three representative nodes from each risk group. The MST was 78.5 months for terminal node 1 in the low-risk group, 15.1 months for terminal node 10 in the medium-risk group, and 6.7 months for terminal node 9 in the high-risk group (log rank P

Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial.

Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study.

Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients.

Association between polymorphisms of DNA repair genes and survival of advanced NSCLC patients treated with platinum-based chemotherapy

Potentially functional polymorphisms in DNA repair genes and non-small-cell lung cancer survival: a pathway-based analysis.

Novel Genetic Variants of SYK and ITGA1 Related Lymphangiogenesis Signaling Pathway Predict Non-Small Cell Lung Cancer Survival.

Genetic Variations in the Transforming Growth Factor-β1 Pathway May Improve Predictive Power for Overall Survival in Non-small Cell Lung Cancer

Novel Genetic Variants in Genes of the Fc Gamma Receptor-Mediated Phagocytosis Pathway Predict Non-Small Cell Lung Cancer Survival.

Potentially functional variants of INPP5D and EXOSC3 in immunity B cell-related genes are associated with non-small cell lung cancer survival

The Association of Genetic Polymorphisms of TNFα, TNF-R1, and TNF-R2 and Lung Cancer Chemotherapy Response

Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer

Inflammation-related genetic variations and survival in patients with advanced non-small cell lung cancer receiving first-line chemotherapy.

Genetic Variants of BCL2 Gene Predict Clinical Outcomes of Non-Small-cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy in a Chinese Population.

Prognostic Assessment of Apoptotic Gene Polymorphisms in Non-Small Cell Lung Cancer in Chinese

Genetic Variants in Cytokine Signaling Pathways and Clinical Outcomes in Early-Stage Lung Cancer Patients

Novel genetic variants of <i>KIR3DL2</i> and <i>PVR</i> involved in immunoregulatory interactions are associated with non-small cell lung cancer survival

Potentially Functional Genetic Variants in the Complement-Related Immunity Gene-Set Are Associated with Non-Small Cell Lung Cancer Survival.

The P38α Rs3804451 Variant Predicts Chemotherapy Response and Survival of Patients with Non-Small Cell Lung Cancer Treated with Platinum-Based Chemotherapy.

Potentially Functional Variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related Pathway Predict Non-Small Cell Lung Cancer Survival

Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.

Germline Predictors of Outcome in Non-small Cell Lung Cancer